Management of ovarian cancer: An impressive history of improvement in survival and quality of life

ONCOLOGY

Volumn 20, Issue 4, 2006, Pages 347-354

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TAMOXIFEN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ANAPHYLAXIS; AREA UNDER THE CURVE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG TOLERABILITY; HUMAN; HYPOMAGNESEMIA; KIDNEY DISEASE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; VOMITING; DRUG RESISTANCE; FEMALE; MORTALITY; OVARY TUMOR; PSYCHOLOGICAL ASPECT; SURVIVOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG RESISTANCE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; SURVIVORS;

EID: 33750135927     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Katz ME, Schwartz PE, Kapp DS, et al: Epithelial carcinoma of the ovary: Current strategies. Ann Intern Med 95:98-111, 1981.
2. Greene MH, Boice JD, Greer BE, et al: Acute nonlymphocytic leukemia after therapy with alkylating-agents for ovarian-cancer - a study of five randomized clinical-trials. N Engl J Med 307:1416-1421,1982.
3. Reimer RR, Hoover R, Fraumeni JF, et al: Acute-leukemia following alkylating agent therapy of ovarian cancer. N Engl J Med 297:177-180, 1977.
4. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. BMJ 303:884-893, 1991.
5. Aabo K, Adams M, Adnitt P, et al: Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78:1479-1487, 1998.
6. Neijt JP, Bokkel Huinink WW, van der Burg ME, et al: Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2:594-600, 1984.
7. Omura G, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 57:1725-1730, 1986.
8. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000.
9. Samson DJ, Seidenfeld J, Ziegler K, et al: Chemotherapy sensitivity and resistance assays: A systematic review. J Clin Oncol 22:3618-3630, 2004.
10. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992.
11. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992.
12. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003.
13. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
14. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691, 2004.
15. Markman M, Kennedy A, Webster K, et al: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19:1901-1905, 2001.
16. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000.
17. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995.
18. Gore M, Mainwaring P, A'Hern R, et al: Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16:2426-2434, 1998.
19. Jakobsen A, Bertelsen K, Andersen JE, et al: Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198, 1997.
20. Lambert HE, Rustin GJ, Gregory WM, et al: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group study. Ann Oncol 8:327-333, 1997.
21. Bertelsen K, Jakobsen A, Stroyer J, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49:30-36, 1993.
22. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289, 1992.
23. von Gruenigen VE, Karlen JR, Waggoner SE: A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 89:532-535, 2003.
24. Markman M, Hakes T, Barakat R, et al: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer. J Clin Oncol 14:796-799, 1996.
25. Rohl J, Kushner D, Markman M: Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol. 81:201-205, 2001.
26. Zanotti KM, Belinson JL, Kennedy AW, et al: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79:211-215, 2000.
27. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003.
28. Markman M: Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 14:15-28, 1993.
29. Dedrick RL, Myers CE, Bungay PM, et al: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11, 1978.
30. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996.
31. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001.
32. Armstrong DK, Bundy B, Wenzel L, et al: Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: A Gynecologic Oncology Group study. N Engl J Med 354:34-43, 2006.
33. Markman M, Walker JL: Intraperitoneal chemotherapy of ovarian cancer: A review with a focus on practical aspects of treatment. J Clin Oncol (in press) 2006.
34. Trimbos JB, Parmar M, Vergote I, et al: International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95:105-112, 2003.
35. Elit L, Chambers A, Fyles A, et al: Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer 101:1926-1935, 2004.
36. Markman M: Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies. Cancer 98:885-887, 2003.
37. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005.
38. Markman M: Viewing ovarian cancer as a "chronic disease": What exactly does this mean? Gynecol Oncol 100:229-230, 2006.
39. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991.
40. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990.
41. Markman M, Kennedy A, Webster K, et al: Continued chemosensitivity to cisplatin/ carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 65:434-436, 1997.
42. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
43. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003.
44. Sabbatini P, Spriggs D: Salvage therapy for ovarian cancer. Oncology (Williston Park) 12:833-843, 1998.
45. Markman M: Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer? Gynecol Oncol 83:449-450, 2001.
46. Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004.
47. Vergote I, De W, I, Tjalma W, et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71:431-436, 1998.
48. Mazzeo F, Berliere M, Kerger J, et al: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90:163-169, 2003.
49. Davidson SA, Rubin SC, Mychalczak B, et al: Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer. Gynecol Oncol 51:349-354, 1993.